FDA — authorised 8 December 2008
- Application: NDA022244
- Marketing authorisation holder: EISAI INC
- Local brand name: LUSEDRA
- Indication: SOLUTION — INTRAVENOUS
- Status: approved
FDA authorised Lusedra on 8 December 2008
Yes. FDA authorised it on 8 December 2008.
EISAI INC holds the US marketing authorisation.